Clinical study of Sintilimab combined targeted therapy for intermediate and advanced primary liver cancer
Objective To explore the clinical effect of Sintilimab combined targeted therapy on intermediate and advanced primary liver cancer(PLC).Methods 84 patients with PLC treated from September 2019 to June 2023 at funan county people's hospital and the north district were involved and divided into two groups by random number method.The control group(42 cases)was treated with Sintilimab,and the observation group(42 cases)was treated with Sintilimab combined with bevacizumab.After 3 cycles of treatment,the levels of serum markers related to angiogenesis and tumor were measured by enzyme-linked immunosorbent assay,and the levels of immune markers were measured by flow cytometry.Kapkan-Meier curve was used for the survival analysis.Results After treatment,the disease control rate(64.29％vs 92.86％)and objective response rate(42.86％vs 76.19％)in the observation group were higher than those in the control group,and the mortality rate(23.81％vs 47.62％)was lower than that in the control group(P＜0.05).The levels of CEA,AFP,CA19-9 and DCP in the observation group[(16.7±3.3)ng/mL,(138.7±27.7)ng/mL,(142.7±20.3)U/mL,(30.5±4.3)mAU/mL,respectively]were significantly lower than those in the control group[(21.4±4.2)ng/mL,(176.2±35.2)ng/mL,(165.6±23.6)U/mL,(35.2±5.1)mAU/mL,respectively](P＜0.05).The levels of CD3+and CD4+/CD8+in the observation group[(72.9±4.8)％,(1.7±0.4)]were significantly higher than those in the control group[(68.4±4.5)％,(1.4±0.3)](P＜0.05).The levels of VEGF,MMP-9 and Ang-2 in the observation group were[(22.5±4.3)ng/mL,(40.5±5.2)mg/L,(21.6±3.6)μg/L,respectively]were significantly lower than those in the control group[(26.4±5.1)ng/mL,(44.6±5.5)mg/L,(25.1±4.2)μg/L](P＜0.05).Conclusion Sintilimab combined with bevacizumab is effective in the treatment of advanced PLC.The levels of tumor markers and angiogenesis-related factors are decreased,the immune function and survival rate are improved,and the drug is safe.
Primary liver cancerMiddle and late stageSindilimabBevacizumabClinical effect
万方数据
维普
